Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Therapeutic Efficacy and Safety of Mirabegron , a β3-Adrenoceptor Agonist, Treatment on Patients With Overactive Bladder Syndrome in Taiwan - Comparison of Therapeutic Efficacy and Safety Between 25mg and 50mg

NCT03044912 is registered in ClinicalTrials.gov with Buddhist Tzu Chi General Hospital as lead sponsor.

NCT NCT03044912
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03044912 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Therapeutic Efficacy and Safety of Mirabegron , a β3-Adrenoceptor Agonist, Treatment on Patients With Overactive Bladder Syndrome in Taiwan - Comparison of Therapeutic Efficacy and Safety Between 25mg and 50mg
Lead sponsor
Buddhist Tzu Chi General Hospital
Phase
Phase 3
Overall status
Unknown status
Start date
November 16, 2015
Completion date
August 1, 2019
Enrollment
574 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

overactive bladder syndrome